Supplementary Figure 1 . Direct costs of antineoplastic and supportive treatment for progressive multiple myeloma in a tax-based health system This table contains the Anatomical The
Introduction: In the ICARIA-MM trial, isatuximab plus pomalidomide-dexamethasone (Pd) significantly prolonged progression-free survival, compared with Pd alone, in patients with relapsed or refractory
Multiple myloma (MM) is a cancer of plasma cells and is on the rise worldwide, particularly in the US, Australia, and Western Europe. Nearly 2% of cancer diagnoses and more than 2% of cancer deaths in
